Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification.

Acta Neuropathol · 2023 · PMC10119222 · PMID 37014508

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

marginally significantp = 0·06so close (0.05 < p ≤ 0.1)

Within subgroup 7, metastatic status was marginally significant (HR 4·45, 0·91–21·71 [95% CI], p = 0·06; Fig. 1 f, p = 0·04, log-rank test; Fig. 1 i).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.